Heron Therapeutics' APONVIE Included in New PONV Management Guidelines
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 04 2025
0mins
Heron Therapeutics announced the inclusion of APONVIE injectable emulsion in the newly released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting: Executive Summary and Full Report as published in Anesthesia and Analgesia. PONV impacts about 30% of postoperative patients in the general surgical population and up to 80% of high-risk patients and is a major cause of patient dissatisfaction after surgery, with patients ranking vomiting as the most undesirable outcome when asked about postsurgical complications. The PONV Guidelines name APONVIE as an NK-1 receptor antagonist option for the prevention of PONV in adults and note APONVIE's long half-life and 30-second IV administration, which provides for quicker onset than oral formulations and a long-acting profile. The PONV Guidelines also provide evidence that aprepitant alone or in combination therapies significantly reduced the risk of PONV and that aprepitant is comparable or superior to ondansetron for PONV prophylaxis. The PONV Guidelines also cite evidence for aprepitant's significant impact on postoperative vomiting.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like HRTX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on HRTX
Wall Street analysts forecast HRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRTX is 4.50 USD with a low forecast of 3.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.330
Low
3.00
Averages
4.50
High
6.00
Current: 1.330
Low
3.00
Averages
4.50
High
6.00
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Heron Therapeutics Reports Q4 2025 Net Revenue of $40.5M Driven by ZYNRELEF and APONVIE
- Revenue Growth: Heron Therapeutics reported approximately $40.5 million in net revenue for Q4 2025, reflecting significant growth compared to the previous year, driven particularly by strong momentum in its Acute Care franchise, especially ZYNRELEF and APONVIE.
- Product Performance: ZYNRELEF generated approximately $12.5 million in net revenue in Q4, marking the largest quarter-over-quarter revenue increase within the portfolio, indicating successful market acceptance and sales strategies.
- Diversified Revenue Streams: CINVANTI and APONVIE contributed approximately $22.9 million and $3.8 million in net revenue for Q4, respectively, enhancing the diversity of the company's revenue sources and reducing reliance on any single product.
- Annual Performance: Total net revenue for FY25 was approximately $154.9 million, reflecting ongoing progress and growth potential across all business areas, suggesting a positive outlook for future developments.
Continue Reading
Heron Therapeutics Reports $154.9M Net Revenue for 2025
- Revenue Growth: Heron Therapeutics reported approximately $40.5 million in net revenue for Q4 2025, reflecting strong momentum in its Acute Care franchise, particularly driven by ZYNRELEF® and APONVIE®.
- Product Performance: ZYNRELEF® generated about $12.5 million in net revenue in Q4, marking a ~35% increase from Q3, indicating sustained demand in the postoperative pain management market and enhancing the company's competitive edge.
- Diversified Revenue Streams: CINVANTI® and SUSTOL® achieved net revenues of approximately $22.9 million and $1.3 million in Q4, respectively, further solidifying Heron's market position in the prevention of chemotherapy-induced nausea and vomiting.
- Strategic Outlook: With total net revenue of approximately $154.9 million for 2025, Heron demonstrates ongoing innovation and market expansion capabilities in the biotechnology sector, laying a solid foundation for future growth.
Continue Reading